JY
GRCE

Jeff Yass’s Grace Therapeutics GRCE Stock Holding History

Jeff Yass’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,200
Closed -$288K – 14802
2026
Q1 		$288K Buy
+62,200
New +$244K ﹤0.01% 10951

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Jeff Yass's GRCE Position: Q2 2026 in Review

Jeff Yass opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 49,577 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #12415 among its holdings. This is a return to the name: Jeff Yass previously reported a position in GRCE as recently as Q2 2024.

Jeff Yass first reported a position in GRCE in Q4 2014 and has held it in 7 quarters since. The position peaked at $528K in Q4 2017. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Jeff Yass held 49,577 shares of Grace Therapeutics worth $113K as of Q2 2026.
  • Grace Therapeutics was a new Jeff Yass position in Q2 2026.
  • Grace Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12415 holding.
  • Jeff Yass first reported a position in Grace Therapeutics in Q4 2014 and has held it in 7 quarters since.
  • Jeff Yass's Grace Therapeutics position peaked at $528K in Q4 2017.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.